Startup | October 26, 2021
Healthium Medtech introduces surgical wound dressing product
Expands wound care portfolio and aims to drive greater market penetration and availability in the wound dressing category
Expands wound care portfolio and aims to drive greater market penetration and availability in the wound dressing category
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
Strengthens supply chain continuity with first manufacturing facility outside of the U.S.
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
This strategic collaboration will enable continued innovation in cancer care
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
Subscribe To Our Newsletter & Stay Updated
